The End of Smoking? Medical Cannabis Enters Its Next Phase

A major shift is unfolding in global cannabis policy—and it’s coming from one of the most medically advanced cannabis markets in the world. According to recent developments reported by The Times of Israel, a health ministry panel in Israel is advising a halt to smoking medical cannabis, while actively supporting alternative delivery methods.

At the core of the recommendation is a clinical concern: smoking cannabis, even in a medical context, is difficult to standardize. Dosing becomes inconsistent, absorption varies from patient to patient, and long-term respiratory risks remain difficult to quantify. Israeli regulators are now moving toward a pharmaceutical-style framework—where cannabis is treated less like a plant and more like a controlled therapeutic compound.

The data driving this shift is significant. Medical cannabis use in Israel has surged dramatically in recent years, with a sharp increase in high-THC consumption and a majority of patients relying on smokable formats.   This raised concerns among policymakers about dependency risks, lack of dosage control, and the broader public health implications of widespread smoking as a “medical” method.

The proposed solution is not prohibition—but evolution. Regulators are advocating for alternatives such as vaporizers, inhalers, oils, and extracts that allow for more precise dosing and medical oversight. In fact, smoking could be phased out entirely over the next few years, with exceptions only in rare, medically justified cases.

This is where the conversation becomes bigger than Israel. What we’re seeing is a global pivot: cannabis is being pulled deeper into the healthcare system. Prescription-based models, tighter monitoring, and standardized formats are becoming the new benchmark. The shift reflects a broader question—should cannabis remain a lifestyle product, or fully transition into a regulated medical treatment?

For markets like New York, this signals what’s coming next. As legalization matures, expect increased scrutiny on how cannabis is consumed—not just whether it’s legal. Delivery methods, potency, and patient tracking will likely become central to future regulation.

At Elevated Club NYC, this reinforces a simple principle: evolution is part of elevation. As the industry advances, so does the expectation for quality, consistency, and informed use. Whether through flower, concentrates, or alternative formats, the future of cannabis will be defined by how precisely it can meet individual needs.

The takeaway is clear—cannabis isn’t moving backward. It’s moving toward structure, science, and a more refined experience.